Ceredase review

The Ceredase injection, also known by its generic name Alglucerase, is a modified version of the -glucocerebrosidase enzyme, also known as -D-glucosyl-N-acylsphingosine glucohydrolase, EC Ceredase and glucocerebrosidase act as catalysts to the glycolipid's hydrolysis (glucocerebroside) inside the lysosomes of the reticuloendothelial system.

This enzyme is utilized as a medicament to restore the deficiencies found in patients suffering from Gaucher's illness. This medicament decreases complications and relieves symptoms associated with the aforementioned condition.

Ceredase can be taken via intravenous infusion over the course of one to two hours. Each dose should be administered on a case-to-case basis depending on the patient. Dosage may vary from 2.5 units per kilogram of body weight given three times a week to a maximum of 60 units per kilogram given once a week or once a month. 60 units per kilogram every two weeks is the most common dose used, and it's also the dose where most information on Ceredase's effectiveness is available.

If your condition is particularly severe, the medicament may be given at a higher amount or given to you frequently from the very start. Once a positive response to the medicament has been achieved, dosage can be reduced in order to begin maintenance treatment of the patient. Gradual reductions can be done at intervals of three to six months while carefully analyzing the patient's response to the decreasing doses.

Tests conducted with over one thousand patients treated with this medicament have yielded a small number of different side effects. Some of these issues are connected with the administration route. For example, the site of venipuncture sometimes produces sterile abscess, swelling, burning, pruritus, and discomfort. The remaining side effects include emesis, nausea, abdominal discomfort, chills, and slight fever. None of the above side effects are severe enough to require medical intervention.

Conversely, during rare cases of hypersensitivity, the following symptoms have happened during or shortly after infusions: abdominal cramping, chest discomfort, symptoms of respiratory disorder, nausea, urticaria, angioedema, pruritus, and flushing. Hypotension has been known to occur during a few of these instances.

Inform your healthcare specialist immediately of any OTC (over the counter) or prescription medicaments you may be taking. More to the point, you must not begin or halt any treatment without prior doctor or pharmaceutical approval. You must also tell your physician if you have any allergies or other diseases before starting therapy. If you're pregnant, you should only use Ceredase when clearly needed. Lastly, consult your doctor before breastfeeding while under Ceredase treatment.

The Ceredase solution should never be shaken and each bottle should be examined carefully for any discoloration or particulate matter before being used. Any bottles suffering from discoloration or exhibiting particulate matter should be discarded. What's more, you must not use this medicament once it has already passed its expiration date.

Studies have shown that about 13% of patients have developed the IgG antibody after one year of Ceredase therapy. This phenomenon usually occurs within six months of treatment; patients who don't develop the IgG antibody within this period will rarely develop it after a year of treatment.

About a quarter of the studied patients with IgG antibodies underwent hypersensitivity symptoms. Simply put, those who've developed antibodies from Ceredase therapy have a higher risk of also developing an allergic reaction.

• Molecular formula of ceredase is C2532H3854N672O711S16
• Chemical IUPAC Name is Human Beta-glucocerebrosidase
• Molecular weight is 55597.4 g/mol

Generic name: Alglucerase

Brand name(s): Imiglucerase

  Your Ceredase review